Acticor Biotech: Publication of 2024 half-year financial results

Acticor Biotech announces its financial results for the first half of 2024, approved by the Board of Directors. The company, specialized in the development of cardiovascular treatments, did not generate any revenue. Research and development expenses amounted to €4,244K, down from the previous year. General expenses increased, reaching €2,692K. The net loss for the period is €7,305K, compared to €9,471K last year. Cash is €4.8M.

The receivership procedure continues, with an extension of the call for tenders until November 5, 2024 to find new investors. Acticor Biotech is also continuing the development of glenzocimab, with a focus on the treatment of myocardial infarction in the LIBERATE clinical study. Results are expected by the end of 2026.